HRYZ (Shanghai) Biotech Co., Ltd.

Primary objectives: To evaluate the safety and tolerability of HRYZ-T101 injection in the treatment of patients with recurrent or metastatic HPV18-positive solid tumors who have failed standard treatment, and to determine the recommended dose (RP2D) for the Phase II clinical trial. Secondary objectives: (1) To preliminarily explore the clinical efficacy of HRYZ-T101 injection in the treatment of patients with recurrent or metastatic HPV18-positive solid tumors who have failed standard treatment; (2) To evaluate the activation, expansion and survival of TCR-T cells in the subjects after administration of HRYZ-T101 injection; (3) To evaluate the changes in peripheral blood cytokine levels and inflammatory markers after administration of HRYZ-T101 injection.